Laurus Labs stock

LAURUSLABS · NSE · INR

Compare Laurus Labs
₹2,294.60Change from previous close: −0.49%Absolute change: −₹11.40

Close · November 20, 2026

Price history

+132.46% over the period

1 year: from ₹987.10 (November 20, 2025) to ₹2,294.60 (November 20, 2026), +132.46%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026₹2,294.60
October 30, 2026₹2,405.50
September 30, 2026₹1,980.00
August 31, 2026₹1,915.00
July 31, 2026₹1,816.20
June 30, 2026₹1,517.40
May 29, 2026₹1,362.00
April 30, 2026₹1,100.95
March 30, 2026₹992.70
February 27, 2026₹1,075.80
January 30, 2026₹965.00
December 31, 2025₹1,108.00
November 28, 2025₹1,031.35
November 20, 2025₹987.10

At a glance

  • The company

    Manufactures medicines, active pharmaceutical ingredients and recombinant proteins for global pharmaceutical markets

  • Latest results

    Quarter to September 30, 2026 · EPS ₹8.20 (estimate ₹6.66)

TickerLandia's take on Laurus Labs

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low₹917.95
52-wk high₹2,488.00

−7.77% from the 52-week high

Analysts · 15 analysts

Average target₹2,156.29−6.03% vs. price

Buy 8 · Hold 3 · Sell 4 · Hold

TickerLandia Fingerprint: Laurus Labs

Compared with similar companies: very strong momentum, very high price, and very low dividend.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Laurus Labs is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2026), Laurus Labs's P/E today is 139.5, above the median of its last 10 fiscal years (35.2; between 13.6 and 132.1 from 2017 to 2026). Laurus Labs's P/E (trailing 12 months): 97.8, +241% against the median of a group of 11 similar companies (28.7).

P/E compared with its history

Compared with 11 similar companies

Laurus Labs's metrics compared with similar companies
MetricLaurus LabsPosition in the groupBand
P/E (trailing 12 months)97.8High
Forward P/E68.4High
Operating margin24.1%Middle
ROE24.0%High
Debt/equity0.42High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Laurus Labs. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

₹22.06B

Latest quarter · Q3 2026

Net income

₹4.41B

Latest quarter · Q3 2026

Quarterly net margin

20.0%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
₹1.31T
P/E
97.8
EPS
₹24.78
Volume
2.28M
Daily trading
€68.26M
Dividend yield
0.10%
Last ex-dividend on November 6, 2026

How Laurus Labs is changing

All results
  • Revenue grew 7.2% a year on average over the last 5 years

  • Operating margin fell from 21.4% to 19.1%

  • Less cash than profit: free cash flow equal to 36% of net income

Returns

Laurus Labs returns with dividends

₹1,000 invested in Laurus Labs 5 years ago, on November 22, 2021, would be worth ₹4,931 today with dividends reinvested: +393.15% in total, +37.65% per year. On price alone it would be ₹4,863 (+386.30%).

PeriodLaurus Labs₹1,000 becomes
1 month+14.02%₹1,140
6 months+68.58%₹1,686
Year to date+107.09%₹2,071
1 year+132.79%₹2,328
3 years+526.78%₹6,268
5 years+393.15%₹4,931

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Laurus Labs: technical analysis

Laurus Labs is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 6.5% below its all-time closing high (₹2,454.00, November 9, 2026).

Trend
Upward
RSI (14 sessions)
54
Between 30 and 70
vs 200-session average
+47.28%

Support and resistance

Price areas where Laurus Labs has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price₹2,294.60
  3. Support₹1,944.87−15.24%3 touches, last on October 23, 2026
  4. Support₹1,867.15−18.63%2 touches, last on September 16, 2026
  5. Support₹1,452.60−36.69%2 touches, last on July 8, 2026

Volatility and risk

Volatility (60 sessions, annualised)
37.5%
Largest fall in the last year
−16.27%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Laurus Labs: seasonality

Average monthly price change over 10 years

−3.7%Jan+1.1%Feb+0.5%Mar+10.7%Apr+2.6%May+6.5%Jun+12.3%Jul+4.0%Aug+1.6%Sep−0.1%Oct+2.6%Nov+4.3%Dec

Over the last 10 years, the strongest month for Laurus Labs has been July: +12.35% on average, positive in 5 years out of 10. The weakest has been January: −3.72% on average, positive in 1 years out of 10. November, the current month, has been positive in 4 years out of 9 (+2.61% on average).

Show chart data
MonthAverageMedianPositive years
January−3.72%−3.97%1 of 10
February+1.13%+3.30%6 of 10
March+0.46%−1.07%5 of 10
April+10.75%+3.34%7 of 10
May+2.64%−0.89%5 of 10
June+6.55%+9.16%7 of 10
July+12.35%+4.52%5 of 10
August+3.96%+2.63%6 of 10
September+1.57%−1.35%3 of 10
October−0.05%+2.37%5 of 10
November+2.61%−0.80%4 of 9
December+4.32%+5.95%7 of 9

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Laurus Labs and its competitors

Generic APIs and solid oral drug products for anti-retroviral treatments open the offering of Laurus Labs Limited, which manufactures and sells medicines and active pharmaceutical ingredients in India and internationally through its subsidiaries. Its range extends to anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology and gastroenterology products, supplied as intermediates and finished dosages. The group also develops recombinant proteins and cell-culture media supplements free of animal-origin materials, provides drug substance, drug product and biologics development services, and offers rare disease therapeutics.

Headquarters
Hyderabad, India
Employees
7,059
Founded
2005
Chief executive
Satyanarayana Chava
Laurus Labs and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Laurus LabsLAURUSLABS$14.13B24.1%97.8+68.58%
Yunnan Baiyao Group000538$15.07B11.2%19.4+11.07%
Zydus LifesciencesZYDUSLIFE$12.92B17.2%28.7+15.29%
PharmaEssentia6446$15.94B38.4%74.1+54.65%
CiplaCIPLA$12.34B13.0%39.5+1.11%
Shionogi4507$16.75B31.6%11.2+2.83%

Same industry or related industries, similar size. Compare Laurus Labs with its competitors · Full profile